2-tetrahydropyran-2-yloxy-5-(trifluoromethyl)benzaldehyde | 888972-21-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-tetrahydropyran-2-yloxy-5-(trifluoromethyl)benzaldehyde
• 英文别名: 2-[(tetrahydro-2H-pyran-2-yl)oxy]-5-(trifluoromethyl)-benzaldehyde；2-[(Tetrahydro-2h-pyran-2-yl)oxy]-5-(trifluoromethyl)-benzaldehyde；2-(oxan-2-yloxy)-5-(trifluoromethyl)benzaldehyde
• CAS: 888972-21-2
• 化学式: C₁₃H₁₃F₃O₃
• 分子量: 274.24
• InChiKey: YVVFBQVKOXLXLK-UHFFFAOYSA-N

物化性质

• 沸点：
  351.7±42.0 °C(Predicted)
• 密度：
  1.292±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-tetrahydropyran-2-yloxy-5-(trifluoromethyl)benzaldehyde 在 盐酸 、 TEA 、 3-乙基-5-(2-羟乙基)-4-甲基噻唑溴化物 、 potassium carbonate 、 对甲苯磺酸 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 3-{2-[5-trifluoromethyl-2-(hydroxy)phenyl]-5-methyl-pyrrol-1-yl}-benzoic acid ethyl ester
  参考文献：
  名称：

  Structure–activity relationships of 1,5-biaryl pyrroles as EP1 receptor antagonists

  摘要：

  The preliminary SAR of a series of novel 1,5-biaryl pyrrole EP1 receptor antagonists derived from compound 1 is described. Replacement of the benzyl group of 1 with isosteric groups was investigated. The most effective replacement was found to be the isobutyl group. The cyclopentylmethyl and cyclohexylmethyl groups were also effective benzyl replacements. The cyclohexylmethyl derivative 19 demonstrated the lowest metabolic clearance within this series. In addition, several high affinity substituted benzyl analogues were also identified. Compound 39 was found to have good bioavailability in rats and demonstrated efficacy in the established FCA preclinical model of inflammatory pain with a calculated ED50 of 9.2 mg/kg. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.073
• 作为产物：
  描述：

  对三氟甲基苯酚 在 正丁基锂 、 4-甲基苯磺酸吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 2-tetrahydropyran-2-yloxy-5-(trifluoromethyl)benzaldehyde
  参考文献：
  名称：

  探索苯基丙酸作为游离脂肪酸受体4（FFA4）的激动剂：鉴定口服有效的FFA4激动剂

  摘要：

  长链游离脂肪酸受体4（FFA4 / GPR120）最近被认为是脂质传感器，在营养物传感和炎症中起着重要作用，因此具有作为2型糖尿病和代谢综合征的治疗靶标的潜力。为了探索在代谢性疾病动物模型中刺激该受体的作用，我们启动了鉴定具有适当药代动力学特性的激动剂的工作，以支持进入体内研究的进程。对一系列苯丙酸的广泛SAR研究导致鉴定出化合物29，一种在两种2型糖尿病临床前模型中降低血浆葡萄糖的FFA4激动剂。

  DOI：

  10.1016/j.bmcl.2017.01.034

文献信息

• A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors
  作者：Cecilia Mattsson、Peder Svensson、Clas Sonesson

  DOI：10.1016/j.ejmech.2013.11.035

  日期：2014.2

  A series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones (coumarins) have been synthesized and their inhibitory activity to human monoamine oxidase A (MAO A) and B (MAO B) determined. Incorporation of a basic amino function in the C3 position together with substitution at the C6 position produced novel coumarin compounds with selectivity for the MAO A subtype. Substitution in the C6 position

  已经合成了一系列的6-取代的3-（吡咯烷-1-基甲基）铬-2-酮（香豆素），并确定了它们对人单胺氧化酶A（MAO A）和B（MAO B）的抑制活性。在C3位上结合基本氨基官能团以及在C6位上取代产生了对MAOA A亚型具有选择性的新型香豆素化合物。在C6位置被较小的亲水基团取代，例如羟基（19，IC 50  = 1.46μM）或氨基（18，IC 50  = 3.77μM），是MAO A最有效和最具选择性的化合物。这些化合物还显示出优异的水溶性特性。给予化合物18 [6-氨基-3-（吡咯烷-1-基甲基）铬-2--2-]体内在大鼠脑中诱导的典型MAO A抑制神经递质代谢产物特征：3,4-二羟基苯基乙酸（DOPAC）和5-羟基吲哚乙酸（5-HIAA）降低，但3-甲氧基酪胺（3-MT）水平升高。
• Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases
  申请人：Alcaraz Lilian

  公开号：US20090149448A1

  公开（公告）日：2009-06-11

  The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

  本发明涉及用于治疗呼吸系统疾病的取代苯氧乙酸类化合物作为有用的药物化合物，包含这些化合物的药物组合物以及它们的制备方法。
• Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
  申请人：Amorepacific Corporation

  公开号：EP1857440A1

  公开（公告）日：2007-11-21

  This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.

  本发明涉及作为类香草素受体（Vanilloid Receptor 1; VR1; TRPV1）拮抗剂的新型化合物、其异构体或其药学上可接受的盐；以及含有这些化合物的药物组合物。 本发明提供了一种药物组合物，用于预防或治疗疼痛、偏头痛、关节痛、神经痛、神经病变、神经损伤、皮肤病、膀胱过敏、肠易激综合征、便急、呼吸系统疾病、皮肤、眼睛或粘膜刺激、胃十二指肠溃疡、炎症性疾病、耳病和心脏病等疾病。
• Studies towards the conception of new selective PPARβ/δ ligands
  作者：Carine Ekambomé Basséne、Franck Suzenet、Nathalie Hennuyer、Bart Staels、Daniel-Henri Caignard、Catherine Dacquet、Pierre Renard、Gérald Guillaumet

  DOI：10.1016/j.bmcl.2006.06.028

  日期：2006.9

  In order to define new PPAR beta/delta ligands, SAR study on the selective PPAR beta/delta activator L-165,041 led to the identification of one key functional group for selective PPAR beta/delta activation. Further-more, taking advantage of SAR studies done elsewhere on the most selective PPAR beta/delta ligand GW501516, the conception of new ligands showing good affinity for PPAR beta/delta is reported. Finally, synthesis and biological evaluation of pyridine analogues have shown the benefical effect of the pyridine ring on the PPAR beta/ delta subtype selectivity. (c) 2006 Published by Elsevier Ltd.
• WO2006/56752
  申请人：——

  公开号：——

  公开（公告）日：——